OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) has been claimed as a liver phenotype of metabolic syndrome, which in turn is associated with male hypogonadism. We assessed whether an independent association between NAFLD and androgen deficiency could be revealed in men with chronic spinal cord injury (SCI), who exhibit a high prevalence of biochemical androgen deficiency and a combination of risk factors for metabolic syndrome. DESIGN: Fifty-five consecutive men with chronic SCI admitted to a rehabilitation program underwent clinical/biochemical evaluations and liver ultrasonography. RESULTS: NAFLD was diagnosed in 27 patients (49.1%). Men with NAFLD were older and exhibited significantly higher body mass index, Homeostatic model assessment of insulin resistance, triglycerides and gamma-glutamyl transpeptidase values, lower total and free testosterone levels and they were engaged in a significantly poorer weekly leisure time physical activity (LTPA). At the multiple logistic regression analysis, only total and free testosterone levels exhibited a significant independent association with NAFLD. The risk of having NAFLD increased indeed of 1% for each decrement of 1 ng/dL of total testosterone and of 3% for each decrement of 1 pg/mL of free testosterone, after adjustment for confounders. In men with total testosterone < 300 ng/dL (36.4%) the prevalence of NAFLD reached 85%: they had a risk of having NAFLD significantly higher (∼12-fold) than those with total testosterone ≥ 300 ng/dL, after adjustment for confounders. CONCLUSION: The evidence of an independent association between NAFLD and low testosterone is strongly reinforced by its demonstration in men with chronic SCI, in spite of the many confounders peculiar to this population.
OBJECTIVE:Non-alcoholic fatty liver disease (NAFLD) has been claimed as a liver phenotype of metabolic syndrome, which in turn is associated with male hypogonadism. We assessed whether an independent association between NAFLD and androgen deficiency could be revealed in men with chronic spinal cord injury (SCI), who exhibit a high prevalence of biochemical androgen deficiency and a combination of risk factors for metabolic syndrome. DESIGN: Fifty-five consecutive men with chronic SCI admitted to a rehabilitation program underwent clinical/biochemical evaluations and liver ultrasonography. RESULTS: NAFLD was diagnosed in 27 patients (49.1%). Men with NAFLD were older and exhibited significantly higher body mass index, Homeostatic model assessment of insulin resistance, triglycerides and gamma-glutamyl transpeptidase values, lower total and free testosterone levels and they were engaged in a significantly poorer weekly leisure time physical activity (LTPA). At the multiple logistic regression analysis, only total and free testosterone levels exhibited a significant independent association with NAFLD. The risk of having NAFLD increased indeed of 1% for each decrement of 1 ng/dL of total testosterone and of 3% for each decrement of 1 pg/mL of free testosterone, after adjustment for confounders. In men with total testosterone < 300 ng/dL (36.4%) the prevalence of NAFLD reached 85%: they had a risk of having NAFLD significantly higher (∼12-fold) than those with total testosterone ≥ 300 ng/dL, after adjustment for confounders. CONCLUSION: The evidence of an independent association between NAFLD and low testosterone is strongly reinforced by its demonstration in men with chronic SCI, in spite of the many confounders peculiar to this population.
Authors: Thomas G Travison; Andre B Araujo; Varant Kupelian; Amy B O'Donnell; John B McKinlay Journal: J Clin Endocrinol Metab Date: 2006-12-05 Impact factor: 5.958
Authors: David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Jukka T Salonen Journal: J Clin Endocrinol Metab Date: 2004-11-09 Impact factor: 5.958
Authors: L Nikolaenko; Y Jia; C Wang; M Diaz-Arjonilla; J K Yee; S W French; P Y Liu; S Laurel; C Chong; K Lee; Y Lue; W N P Lee; R S Swerdloff Journal: Endocrinology Date: 2013-11-26 Impact factor: 4.736
Authors: David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Riitta Salonen; Jukka T Salonen Journal: Diabetes Care Date: 2004-05 Impact factor: 19.112
Authors: Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey Journal: J Spinal Cord Med Date: 2017-08-03 Impact factor: 1.985
Authors: S D'Andrea; A Martorella; F Coccia; C Castellini; E Minaldi; M Totaro; A Parisi; F Francavilla; S Francavilla; A Barbonetti Journal: Endocrine Date: 2020-09-03 Impact factor: 3.633
Authors: A Barbonetti; S D'Andrea; J Samavat; A Martorella; G Felzani; S Francavilla; M Luconi; F Francavilla Journal: J Endocrinol Invest Date: 2018-05-04 Impact factor: 4.256
Authors: Matthew T Goodus; Kaitlin E Carson; Andrew D Sauerbeck; Priyankar Dey; Anthony N Alfredo; Phillip G Popovich; Richard S Bruno; Dana M McTigue Journal: Exp Neurol Date: 2021-04-30 Impact factor: 5.330